Isopeptidase-Fluorogenic Assays

FXIII-Assay Substance,


10 mg 520 € available

Art. No. A101
Background info Also suitable for TG1, TG2, TG3 and TG6

Factor XIII FXIII assay substance A101 by Zedira
Molecular Formula C80H123F3N20O27 (free base: C78H122N20O25)
Molecular Weight 1853.95 (free base: 1739.92)
Purity by HPLC >95 % (HPLC)
Appearance yellow solid
Solubility 50 μM in 0.1% (v/v) DMSO / aqueous buffers.
Pre-dissolve e.g. 10 mg (5.39 μmol) in 108 μl DMSO - dilute e.g. 10 μl of that stock solution (50 mM) with 9990 μl aqueous buffer to obtain a 50 μM solution. DMSO stock solutions are sterile and can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Application Kinetic measurement of transglutaminases
Storage Store at -20°C, desiccate
Reference(s) Oertel, K. et al. Anal. Biochem. 2007, 367, 152.
Dodt, J. et al. Anal. Biochem. 2013, 439, 145.
Berny‐Lang, M.A. et al. J. Am. Heart Assoc. 2013, 2, e000026.
Schroeder, V. et al. Br. J. Haematol. 2015, 168, 757.
de Jager, M. et al. Neuropathol. Appl. Neurobiol. 2016, 42, 255.
Király, R. et al. Amino Acids 2016, 48, 31.
van der Wildt, B. et al. Nucl. Med. Biol. 2016, 43, 232.
Dodt, J. et al. Br. J. Haematol. 2016, 172, 452.
Chrobok, N.L. et al. PLoS ONE 2018, 13, e0209522.
Akbar, A. et al. J. Med. Chem. 2017, 60, 7910-7927.
Singh, S. et al. Int. J. Mol. Sci. 2019, 20, 2682.
Note The molecular weight was corrected to 1853.95, taking into account that A101 traps only one TFA counter ion instead of two counter ions as stated in PDS RN3.1 from 07 May 2014. The presence of one TFA counter ion is valid for all former batches, too.
Background: During the course of our continuous quality assurance process, Zedira developed a novel method to quantify the TFA counter ion content by using a 19F NMR method according to Little et al. (J. Pharm. Biomed. Anal. 2007, 43, 1324), based on an internal standard.
Please note that neither the synthesis and purification nor the product as such has been changed. Please consider the molecular weight correction if necessary.

Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA